{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2C+Persistent%2C+or+Recurrent+Endometrial+Cancer",
    "query": {
      "condition": "Advanced, Persistent, or Recurrent Endometrial Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T20:15:56.588Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00006089",
      "title": "Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Adenocarcinoma",
        "ERBB2 Gene Amplification",
        "Recurrent Uterine Corpus Carcinoma",
        "Stage III Uterine Corpus Cancer AJCC v7",
        "Stage IV Uterine Corpus Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 34,
      "start_date": "2000-09-18",
      "completion_date": "2010-01-31",
      "has_results": false,
      "last_update_posted_date": "2019-07-31",
      "last_synced_at": "2026-09-23T20:15:56.588Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006089"
    },
    {
      "nct_id": "NCT02725268",
      "title": "A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Neoplasms"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        },
        {
          "name": "MLN1117",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 241,
      "start_date": "2016-04-01",
      "completion_date": "2020-10-30",
      "has_results": true,
      "last_update_posted_date": "2021-11-24",
      "last_synced_at": "2026-09-23T20:15:56.588Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Greenbrae, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02725268"
    },
    {
      "nct_id": "NCT00729586",
      "title": "Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Carcinoma",
        "Recurrent Uterine Corpus Carcinoma",
        "Stage IIIA Uterine Corpus Cancer",
        "Stage IIIB Uterine Corpus Cancer",
        "Stage IIIC1 Uterine Corpus Cancer",
        "Stage IIIC2 Uterine Corpus Cancer",
        "Stage IVA Uterine Corpus Cancer",
        "Stage IVB Uterine Corpus Cancer"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Megestrol Acetate",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen Citrate",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 73,
      "start_date": "2008-09",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-09-23T20:15:56.588Z",
      "location_count": 108,
      "location_summary": "Burbank, California • Palo Alto, California • San Diego, California + 75 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00729586"
    },
    {
      "nct_id": "NCT00377520",
      "title": "A Trial for Patients With Advanced/Recurrent Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms",
        "Neoplasms by Site",
        "Urogenital Neoplasms",
        "Genital Neoplasms, Female",
        "Uterine Neoplasms",
        "Endometrial Neoplasms",
        "Cancer of Endometrium",
        "Endometrial Cancer",
        "Cancer of the Endometrium",
        "Endometrium Cancer",
        "Neoplasms, Endometrial"
      ],
      "interventions": [
        {
          "name": "pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 27,
      "start_date": "2006-09",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2009-11-20",
      "last_synced_at": "2026-09-23T20:15:56.588Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00377520"
    },
    {
      "nct_id": "NCT02228681",
      "title": "Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced, Persistent, or Recurrent Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Medroxyprogesterone Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GOG Foundation",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 74,
      "start_date": "2015-05-21",
      "completion_date": "2024-08-22",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-09-23T20:15:56.588Z",
      "location_count": 26,
      "location_summary": "Aurora, Colorado • Miami, Florida • Columbus, Georgia + 21 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Scarborough",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02228681"
    },
    {
      "nct_id": "NCT03526432",
      "title": "Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 110,
      "start_date": "2018-08-08",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-23T20:15:56.588Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • St Louis, Missouri • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03526432"
    }
  ]
}